30.76
0.05 (0.16%)
| Previous Close | 30.71 |
| Open | 30.68 |
| Volume | 476,113 |
| Avg. Volume (3M) | 618,972 |
| Market Cap | 1,716,854,016 |
| Price / Earnings (TTM) | 23.30 |
| Price / Earnings (Forward) | 20.16 |
| Price / Sales | 4.07 |
| Price / Book | 2.53 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 9.27% |
| Operating Margin (TTM) | -4.67% |
| Diluted EPS (TTM) | 1.11 |
| Quarterly Revenue Growth (YOY) | 4.30% |
| Quarterly Earnings Growth (YOY) | 1,204.50% |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | 164.15 M |
| Levered Free Cash Flow (TTM) | 138.80 M |
| Return on Assets (TTM) | 2.76% |
| Return on Equity (TTM) | 6.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Supernus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.11% |
| % Held by Institutions | 109.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Piper Sandler, 111.31%) | Buy |
| Median | 64.00 (108.06%) | |
| Low | 63.00 (Cantor Fitzgerald, 104.81%) | Buy |
| Average | 64.00 (108.06%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 48.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 09 Oct 2025 | 65.00 (111.31%) | Buy | 49.51 |
| 29 Aug 2025 | 40.00 (30.04%) | Hold | 45.12 | |
| Cantor Fitzgerald | 30 Sep 2025 | 63.00 (104.81%) | Buy | 47.79 |
| 06 Aug 2025 | 46.00 (49.54%) | Buy | 42.44 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KHATTAR JACK A. | - | 49.51 | -59,900 | -2,965,649 |
| NEWHALL CHARLES W III | - | 49.51 | -25,000 | -1,237,750 |
| Aggregate Net Quantity | -84,900 | |||
| Aggregate Net Value ($) | -4,203,399 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 49.51 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NEWHALL CHARLES W III | Director | 09 Oct 2025 | Automatic sell (-) | 25,000 | 49.51 | 1,237,750 |
| KHATTAR JACK A. | Officer | 09 Oct 2025 | Sell (-) | 59,900 | 49.51 | 2,965,649 |
| KHATTAR JACK A. | Officer | 09 Oct 2025 | Option execute | 81,250 | - | - |
| Date | Type | Details |
|---|---|---|
| 27 Aug 2025 | Announcement | Supernus Pharmaceuticals to Participate in September Investor Conferences |
| 05 Aug 2025 | Announcement | Supernus Announces Second Quarter 2025 Financial Results |
| 31 Jul 2025 | Announcement | Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics |
| 28 Jul 2025 | Announcement | Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer |
| 22 Jul 2025 | Announcement | Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |